MX2015010029A - Medicamento profilactico o terapeutico para el estreñimiento. - Google Patents

Medicamento profilactico o terapeutico para el estreñimiento.

Info

Publication number
MX2015010029A
MX2015010029A MX2015010029A MX2015010029A MX2015010029A MX 2015010029 A MX2015010029 A MX 2015010029A MX 2015010029 A MX2015010029 A MX 2015010029A MX 2015010029 A MX2015010029 A MX 2015010029A MX 2015010029 A MX2015010029 A MX 2015010029A
Authority
MX
Mexico
Prior art keywords
therapeutic drug
constipation
prophylactic
drug
useful
Prior art date
Application number
MX2015010029A
Other languages
English (en)
Other versions
MX346453B (es
Inventor
Daisuke Yamamoto
Fusayo Io
Koji Yamamoto
Original Assignee
Taisho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taisho Pharmaceutical Co Ltd filed Critical Taisho Pharmaceutical Co Ltd
Publication of MX2015010029A publication Critical patent/MX2015010029A/es
Publication of MX346453B publication Critical patent/MX346453B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/10—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se proveen nuevos fármacos útiles en la prevención o tratamiento del estreñimiento, en los que están contenidos como ingredientes activos compuestos inhibidores de SGLT1, en particular un compuesto de 4-isopropilfenil glucitol representado por la siguiente fórmula (I), o sales farmacéuticamente aceptables de los mismos. (ver Fórmula).
MX2015010029A 2013-02-04 2014-02-03 Medicamento profilactico o terapeutico para el estreñimiento. MX346453B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2013019754 2013-02-04
PCT/JP2014/052465 WO2014119787A1 (ja) 2013-02-04 2014-02-03 便秘症の予防又は治療薬

Publications (2)

Publication Number Publication Date
MX2015010029A true MX2015010029A (es) 2015-10-30
MX346453B MX346453B (es) 2017-03-17

Family

ID=51262485

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015010029A MX346453B (es) 2013-02-04 2014-02-03 Medicamento profilactico o terapeutico para el estreñimiento.

Country Status (18)

Country Link
US (1) US10022389B2 (es)
EP (1) EP2952206B1 (es)
JP (1) JP5807767B2 (es)
KR (1) KR102078433B1 (es)
CN (1) CN104955481B (es)
AU (1) AU2014213251B2 (es)
BR (1) BR112015017541A2 (es)
CA (1) CA2899834C (es)
ES (1) ES2694110T3 (es)
HK (1) HK1211479A1 (es)
IL (1) IL240192A (es)
MX (1) MX346453B (es)
MY (1) MY176162A (es)
PH (1) PH12015501696A1 (es)
RU (1) RU2648467C2 (es)
SG (2) SG11201506047PA (es)
TW (1) TWI659739B (es)
WO (1) WO2014119787A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019142774A (ja) * 2016-06-20 2019-08-29 大正製薬株式会社 腸内環境改善剤

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2830424C3 (de) 1978-07-11 1982-04-15 Bayer Ag, 5090 Leverkusen alpha -Glucosidase-Inhibitoren
US5651988A (en) 1995-08-18 1997-07-29 Xyrofin Oy Combination osmotic and bulk forming laxatives
ATE469161T1 (de) 2002-08-08 2010-06-15 Kissei Pharmaceutical Pyrazolderivat, dieses enthaltende medizinische zusammensetzung, medizinische verwendung davon, und zwischenprodukt für dessen herstellung
JP2004137245A (ja) 2002-08-23 2004-05-13 Kissei Pharmaceut Co Ltd ピラゾール誘導体、それを含有する医薬組成物、その医薬用途及びその製造中間体
AU2003262262A1 (en) 2002-08-27 2004-03-19 Kissei Pharmaceutical Co., Ltd. Pyrazole derivatives, medicinal composition containing the same, and medicinal use thereof
CN1744916A (zh) 2002-12-04 2006-03-08 橘生药品工业株式会社 预防和治疗高血糖所导致的疾病
DE102004028241B4 (de) 2004-06-11 2007-09-13 Sanofi-Aventis Deutschland Gmbh Neue Fluorglykosidderivate von Pyrazolen, diese Verbindungen enthaltende Arzneimittel und Herstellung dieser Arzneimittel
TWI387454B (zh) 2004-09-02 2013-03-01 Sucampo Ag 治療胃腸道疾病之方法及組成物
JP5067644B2 (ja) 2006-05-19 2012-11-07 大正製薬株式会社 Ｃ−フェニルグリシト−ル化合物
JP5152519B2 (ja) 2006-06-29 2013-02-27 大正製薬株式会社 Ｃ−フェニル１−チオグルシト−ル化合物
TW200817424A (en) 2006-08-04 2008-04-16 Daiichi Sankyo Co Ltd Benzylphenyl glucopyranoside derivatives
TWI499414B (zh) 2006-09-29 2015-09-11 Lexicon Pharmaceuticals Inc 鈉與葡萄糖第２型共同運輸體（ｃｏ-ｔｒａｎｓｐｏｒｔｅｒ ２）的抑制物與其應用方法
CA2672176A1 (en) 2006-12-14 2008-06-19 Taisho Pharmaceutical Co., Ltd. 1-phenyl 1-thio-d-glucitol derivative
GB2447067A (en) 2007-02-20 2008-09-03 Branko R Babic Alteration of osmotic gradients by polyhydroxy compounds
CA2709530C (en) 2007-12-27 2016-02-23 Kissei Pharmaceutical Co., Ltd. Monosebacate of pyrazole derivative
JP5467040B2 (ja) 2008-04-16 2014-04-09 キッセイ薬品工業株式会社 ピラゾール誘導体の１／２フマル酸塩
WO2010095768A1 (en) * 2009-02-23 2010-08-26 Taisho Pharmaceutical Co., Ltd. 4 -isopropylphenyl glucitol compounds as sgltl inhibitors
JP2013224263A (ja) 2010-08-19 2013-10-31 Taisho Pharmaceutical Co Ltd ４−イソプロピルフェニルグルシトール化合物
JP5656092B2 (ja) 2010-08-20 2015-01-21 大正製薬株式会社 ４−イソプロピルフェニルグルシトール化合物の結晶形及びその製造方法
JP5532138B2 (ja) 2010-08-20 2014-06-25 大正製薬株式会社 ４−イソプロピル−６−メトキシフェニルグルシトール化合物
AR087701A1 (es) * 2011-08-31 2014-04-09 Japan Tobacco Inc Derivados de pirazol con actividad inhibidora de sglt1
BR112014027841B1 (pt) 2012-05-07 2022-08-09 Kissei Pharmaceutical Co., Ltd Uso de derivados de pirazola na fabricação de um fármaco para prevenir ou tratar constipação
US9200025B2 (en) 2012-11-20 2015-12-01 Lexicon Pharmaceuticals, Inc. Inhibitors of sodium glucose cotransporter 1

Also Published As

Publication number Publication date
TW201517903A (zh) 2015-05-16
MX346453B (es) 2017-03-17
HK1211479A1 (en) 2016-05-27
SG11201506047PA (en) 2015-09-29
IL240192A0 (en) 2015-09-24
KR20150112949A (ko) 2015-10-07
AU2014213251A1 (en) 2015-08-27
JPWO2014119787A1 (ja) 2017-01-26
RU2648467C2 (ru) 2018-03-26
CA2899834A1 (en) 2014-08-07
CN104955481B (zh) 2017-10-24
AU2014213251B2 (en) 2017-07-20
KR102078433B1 (ko) 2020-02-17
EP2952206A4 (en) 2016-06-15
CA2899834C (en) 2020-09-01
PH12015501696B1 (en) 2015-10-12
PH12015501696A1 (en) 2015-10-12
TWI659739B (zh) 2019-05-21
ES2694110T3 (es) 2018-12-18
US10022389B2 (en) 2018-07-17
SG10201700267PA (en) 2017-02-27
IL240192A (en) 2017-03-30
US20150374735A1 (en) 2015-12-31
WO2014119787A1 (ja) 2014-08-07
EP2952206A1 (en) 2015-12-09
EP2952206B1 (en) 2018-10-24
CN104955481A (zh) 2015-09-30
JP5807767B2 (ja) 2015-11-10
RU2015137671A (ru) 2017-03-10
MY176162A (en) 2020-07-24
BR112015017541A2 (pt) 2017-07-11

Similar Documents

Publication Publication Date Title
PH12018501807A1 (en) Pyrazolopyrrolidine derivatives and their use in the treatment of diseas
MX2019010446A (es) Compuestos de anillos fusionados biciclicos derivados de piridilo como inhibidores de fgfr4.
MX363127B (es) Derivados de benzotiofeno como inhibidores del receptor de estrogeno.
PH12015501996A1 (en) Heterocyclic compounds and uses thereof
MX2020007023A (es) Analogos detiadiazol y metodos para el tratamiento de afecciones relacionadas con la deficiencia del gen de supervivencia de las neuronas motoras (smn).
MX2019003143A (es) Compuesto heterociclico sustituido con alquinilo, su metodo de preparacion y su uso medico.
MX2015003594A (es) Agente terapeutico o profilactico para sindrome de lisis tumoral.
MX2015016344A (es) Derivados de imidazo-pirrolidinona y su uso en el tratamiento de enfermedades.
MX2016006336A (es) Compuestos pirazolopirimidina.
MX2015016421A (es) Derivados de pirazolo-pirrolidin-4-ona como inhibidores de bet y su uso en el tratamiento de enfermedades.
MX364400B (es) Compuestos de tetraciclina.
PH12016502246A1 (en) Carboxamide derivatives
MX2016014946A (es) Derivados de carboxamida.
MX2016006667A (es) Derivados de pirrolo-pirrolona y su uso como inhibidores.
PH12015501696A1 (en) Prophylactic or therapeutic drug for constipation
MX358470B (es) Administracion de eritoran o sales farmaceuticamente aceptables del mismo para tratar infecciones para ortomixovirus.
MX2016005160A (es) Composiciones farmaceuticas que comprenden agentes antibacterianos.
MX2016005539A (es) Composiciones farmaceuticas que comprenden agentes antibacterianos.
NZ719215A (en) Pharmaceutical compositions comprising antibacterial agents
MX367576B (es) Agente terapéutico o profiláctico para esclerosis múltiple.
PH12019501027A1 (en) Therapeutic drug or prophylactic drug for diabetic nephropathy
PH12016502247A1 (en) Carboxamide derivatives

Legal Events

Date Code Title Description
FG Grant or registration